The in vitro activity of sulopenem was assessed against a 2014-2016 collection of 539 urinary isolates of Escherichia coli from Canadian patients using CLSI-defined broth microdilution methodology. A concentration of sulopenem of 0.03 µg/ml inhibited both 50% (MIC50) and 90% (MIC90) of isolates tested; sulopenem MICs ranged from 0.015 to 0.25 µg/ml. The in vitro activity of sulopenem was unaffected by non-susceptibility to trimethoprim-sulfamethoxazole and/or ciprofloxacin, multidrug-resistant (MDR) phenotypes, extended-spectrum β-lactamases (ESBLs), or AmpC β-lactamases.
https://ift.tt/2qwSznO
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου